The role of VISTA in the tumor microenvironment

Abstract

V-domain Ig Suppressor of T cell Activation (VISTA) is a negative immune checkpoint that is expressed on multiple immune cell subsets and has been characterized in T cells, macrophages, and myeloid-derived suppressor cells. As the only immune checkpoint expressed on naïve T cells, VISTA contributes to the maintenance of T cell quiescence and tolerance. VISTA also regulates multiple myeloid cell activities such as chemotaxis, differentiation, and migration. In the context of cancer, antagonistic monoclonal antibody targeting of VISTA has been shown to aid anti-tumor immunity. Furthermore, combination therapies that include other immune checkpoints such as PD-1 or CTLA-4 with VISTA blockade may enhance therapeutic efficacy in a variety of cancers. Combination therapy may help overcome adaptive resistance to individual checkpoint therapies, thereby improving patient outcomes and survival. Here, we summarize the role of VISTA in myeloid cells and T cells within the tumor microenvironment. We discuss the proposed counter-receptors for VISTA, VISTA antibodies currently in development, and the potential for combination therapies with checkpoint inhibitors such as PD-1 and CTLA-4.

Keywords

VISTA / cancer / MDSC / immune checkpoint

References

[1] Weir HK,Stewart SL.Cancer incidence projections in the united states between 2015 and 2050.Prev Chronic Dis2021;18:E59 PMCID:PMC8220959

[2] Sharma P,Wargo JA.Primary, adaptive, and acquired resistance to cancer immunotherapy.Cell2017;168:707-23 PMCID:PMC5391692

[3] Ribas A.Cancer immunotherapy using checkpoint blockade.Science2018;359:1350-5 PMCID:PMC7391259

[4] Wei SC,Allison JP.Fundamental mechanisms of immune checkpoint blockade therapy.Cancer Discov2018;8:1069-86

[5] Wherry EJ.Molecular and cellular insights into T cell exhaustion.Nat Rev Immunol2015;15:486-99 PMCID:PMC4889009

[6] Thommen DS,Müller P.Progression of lung cancer is associated with increased dysfunction of t cells defined by coexpression of multiple inhibitory receptors.Cancer Immunol Res2015;3:1344-55

[7] Xia A,Xu J,Lu XJ.T Cell dysfunction in cancer immunity and immunotherapy.Front Immunol2019;10:1719 PMCID:PMC6659036

[8] Wolchok JD,Gonzalez R.Overall survival with combined nivolumab and ipilimumab in advanced melanoma.N Engl J Med2017;377:1345-56 PMCID:PMC5706778

[9] Le Mercier I,Lines JL.VISTA regulates the development of protective antitumor immunity.Cancer Res2014;74:1933-44 PMCID:PMC4116689

[10] Kakavand H,Menzies AM.Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.Mod Pathol2017;30:1666-76

[11] Gao J,Pettaway CA.VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.Nat Med2017;23:551-5 PMCID:PMC5466900

[12] Broughton TWK,Schaafsma E.Defining the signature of VISTA on myeloid cell chemokine responsiveness.Front Immunol2019;10:2641 PMCID:PMC6877598

[13] Flies DB,Xu H.Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models.J Immunol2011;187:1537-41 PMCID:PMC3150865

[14] ElTanbouly MA,Nowak E.VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance.Science2020;367:eaay0524 PMCID:PMC7391053

[15] Wang L,Lines JL.VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.J Exp Med2011;208:577-92 PMCID:PMC3058578

[16] Mehta N,Mathews II,Huang PS.Structure and functional binding epitope of v-domain Ig suppressor of t-cell activation (VISTA).Cell Rep2019;28:2509-16.e5

[17] Slater BT,Chen L.Structural insight into T cell coinhibition by PD-1H (VISTA).Proc Natl Acad Sci USA2020;117:1648-57 PMCID:PMC6983362

[18] Yum JI.Terminating cancer by blocking VISTA as a novel immunotherapy: hasta la vista, baby.Front Oncol2021;11:658488 PMCID:PMC8085549

[19] Lines JL,Mak J.VISTA is an immune checkpoint molecule for human T cells.Cancer Res2014;74:1924-32 PMCID:PMC3979527

[20] Flies DB,Higuchi T.Coinhibitory receptor PD-1H preferentially suppresses CD4⁺ T cell-mediated immunity.J Clin Invest2014;124:1966-75 PMCID:PMC4001557

[21] Tanbouly MA, Croteau W, Noelle RJ, Lines JL. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.Semin Immunol2019;42:101308

[22] El Tanbouly MA,Smits NC.VISTA Re-programs macrophage biology through the combined regulation of tolerance and anti-inflammatory pathways.Front Immunol2020;11:580187 PMCID:PMC7593571

[23] Wang L,Putra J.Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity.Proc Natl Acad Sci USA2014;111:14846-51 PMCID:PMC4205642

[24] Ceeraz S,Plummer SF.VISTA deficiency accelerates the development of fatal murine lupus nephritis.Arthritis Rheumatol2017;69:814-25 PMCID:PMC5723399

[25] Sergent PA,Pettus J.Blocking the VISTA pathway enhances disease progression in (NZB × NZW) F1 female mice.Lupus2018;27:210-6 PMCID:PMC5753845

[26] Li N,Yuan Y.Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis.Sci Rep2017;7:1485 PMCID:PMC5431161

[27] Flies DB,Chen L.Mechanistic assessment of PD-1H coinhibitory receptor-induced T Cell tolerance to allogeneic antigens.J Immunol2015;194:5294-304 PMCID:PMC4433880

[28] Liu J,Chen W.Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.Proc Natl Acad Sci USA2015;112:6682-7 PMCID:PMC4450438

[29] Shrestha R,Anaka M.Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma.Front Oncol2018;8:269 PMCID:PMC6053505

[30] Zhang M,Zhao W.VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.BMC Cancer2018;18:511 PMCID:PMC5932869

[31] Böger C,Krüger S.The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?.Oncoimmunology2017;6:e1293215 PMCID:PMC5414883

[32] Schoop H,Halske C.Therapy resistance in neoadjuvantly treated gastric cancer and cancer of the gastroesophageal junction is associated with an increased expression of immune checkpoint inhibitors-comparison against a therapy naïve cohort.Transl Oncol2020;13:165-76 PMCID:PMC6931207

[33] Villarroel-Espindola F,Datar I.Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer.Clin Cancer Res2018;24:1562-73 PMCID:PMC5884702

[34] Liao H,Liu S.Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer.Oncol Lett2018;16:3465-72 PMCID:PMC6096210

[35] Mulati K,Matsumura N.VISTA expressed in tumour cells regulates T cell function.Br J Cancer2019;120:115-27 PMCID:PMC6325144

[36] Zong L,Wang W,Yang J.PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia.Histopathology2019;75:421-30

[37] Kuklinski LF,Li Z.VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.Cancer Immunol Immunother2018;67:1113-21

[38] Choi JW,Yun KA.The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression.Sci Rep2020;10:14372 PMCID:PMC7462859

[39] Wu L,Huang CF.Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma.Cancer Immunol Immunother2017;66:627-36

[40] Hou Z,Fei Q.Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer.J Cancer Res Clin Oncol2021;147:517-31 PMCID:PMC7817580

[41] Ghouzlani A,Rafii S,Badou A.The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis.Sci Rep2021;11:21504 PMCID:PMC8563991

[42] He XL,Lu HZ,Wang Z.Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis.Sci Rep2020;10:2662 PMCID:PMC7021832

[43] Loeser H,Gebauer F.The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma.Oncoimmunology2019;8:e1581546 PMCID:PMC6492979

[44] Cao X,Zhou Y.VISTA expression on immune cells correlates with favorable prognosis in patients with triple-negative breast cancer.Front Oncol2020;10:583966 PMCID:PMC7829913

[45] Hernandez-Martinez JM,Zatarain-Barrón ZL,Arrieta O.VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy.J Thorac Dis2018;10:6378-82 PMCID:PMC6344701

[46] Zong L,Zhang M,Xiang Y.VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.Cancer Immunol Immunother2020;69:33-42 PMCID:PMC6949319

[47] Xie S,Qiao Q.Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors.Cancer Immunol Immunother2018;67:1685-94

[48] Kuang L.Potential value of V-domain Ig suppressor of T-cell activation for assessing progn osis in cervical cancer and as a target for therapy.Int J Clin Exp Pathol2020;13:26-37 PMCID:PMC7013368

[49] Binnewies M,Kersten K.Understanding the tumor immune microenvironment (TIME) for effective therapy.Nat Med2018;24:541-50 PMCID:PMC5998822

[50] Érsek B,Cakir U.Melanoma-associated fibroblasts impair CD8+ T cell function and modify expression of immune checkpoint regulators via increased arginase activity.Cell Mol Life Sci2021;78:661-73 PMCID:PMC7581550

[51] Blando J,Higa MG.Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.Proc Natl Acad Sci USA2019;116:1692-7 PMCID:PMC6358697

[52] Wang X,Kong L.PD-L1 expression in human cancers and its association with clinical outcomes.Onco Targets Ther2016;9:5023-39 PMCID:PMC4990391

[53] Kondo Y,Nishii N,Yagita H.Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.Oral Oncol2016;57:54-60

[54] Hong S,Xia H.Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy.Protein Cell2019;10:840-5 PMCID:PMC6834738

[55] Jin J,Xu A.CCL2: An important mediator between tumor cells and host cells in tumor microenvironment.Front Oncol2021;11:722916 PMCID:PMC8354025

[56] Weber R,Hu X.Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors.Front Immunol2018;9:1310 PMCID:PMC6004385

[57] Clavijo PE,Chen J.Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells.Oncotarget2017;8:55804-20 PMCID:PMC5593525

[58] Deng J,Sarde A.Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment.Cancer Immunol Res2019;7:1079-90 PMCID:PMC6606337

[59] Fu LQ,Cai MH,Zhao YY.The roles of tumor-associated macrophages in tumor angiogenesis and metastasis.Cell Immunol2020;353:104119

[60] Ceeraz S,Sergent PA.VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.Arthritis Res Ther2017;19:270 PMCID:PMC5721690

[61] Veglia F.Dendritic cells in cancer: the role revisited.Curr Opin Immunol2017;45:43-51 PMCID:PMC5449252

[62] Wang L,Claxton DF.VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.Oncoimmunology2018;7:e1469594 PMCID:PMC6140587

[63] Xu W,Zheng Y.Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression.Cancer Immunol Res2019;7:1497-510 PMCID:PMC6726548

[64] Ohno T,Kondo Y.The immune checkpoint molecule VISTA regulates allergen-specific Th2-mediated immune responses.Int Immunol2018;30:3-11

[65] Samoszuk M.Eosinophils and human cancer.Histol Histopathol1997;12:807-12

[66] Liu H,Hu L.A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma.Cell Mol Immunol2018;15:838-45 PMCID:PMC6203798

[67] ElTanbouly MA,Schaafsma E.VISTA: a target to manage the innate cytokine storm.Front Immunol2020;11:595950 PMCID:PMC7905033

[68] Kumar V,Tcyganov E.The Nature of myeloid-derived suppressor cells in the tumor microenvironment.Trends Immunol2016;37:208-20 PMCID:PMC4775398

[69] Law AMK,Gallego-Ortega D.Myeloid-derived suppressor cells as a therapeutic target for cancer.Cells2020;9:561 PMCID:PMC7140518

[70] Wang Q,Flies DB,Chen L.Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability.Sci Rep2017;7:6086 PMCID:PMC5519767

[71] Wei SC,Sharma R.Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.Proc Natl Acad Sci USA2019;116:22699-709 PMCID:PMC6842624

[72] Im SJ.Re-defining T-Cell exhaustion: subset, function, and regulation.Immune Netw2020;20:e2 PMCID:PMC7049579

[73] Miller BC,Al Abosy R.Subsets of exhausted CD8⁺ T cells differentially mediate tumor control and respond to checkpoint blockade.Nat Immunol2019;20:326-36

[74] Johnston RJ,Pinckney J.VISTA is an acidic pH-selective ligand for PSGL-1.Nature2019;574:565-70

[75] Wang J,Manick B.VSIG-3 as a ligand of VISTA inhibits human T-cell function.Immunology2019;156:74-85 PMCID:PMC6283650

[76] Rogers BM,Dezso Z.VISTA is an activating receptor in human monocytes.J Exp Med2021;218:e20201601 PMCID:PMC8193568

[77] Yoon KW,Kwon E.Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53.Science2015;349:1261669 PMCID:PMC5215039

[78] Carlow DA,Naus S,Seo W.PSGL-1 function in immunity and steady state homeostasis.Immunol Rev2009;230:75-96

[79] Tinoco R,Takahashi AA.PSGL-1: a new player in the Immune checkpoint landscape.Trends Immunol2017;38:323-35 PMCID:PMC5411281

[80] Matsumoto M,Hirata T.P-selectin glycoprotein ligand-1 negatively regulates T-cell immune responses.J Immunol2009;183:7204-11

[81] Wu H,Beatty M.T-cells produce acidic niches in lymph nodes to suppress their own effector functions.Nat Commun2020;11:4113 PMCID:PMC7431837

[82] Molloy MGY. InventorIdentification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators2016.

[83] VSIG8 the Human Protein Atlas. Available from: https://www.proteinatlas.org/ENSG00000243284-VSIG8 [Last accessed on 15 June 2022].

[84] Mehta N,Kelly RL.An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA.Sci Rep2020;10:15171 PMCID:PMC7494997

[85] Farrugia BL,Melrose J.The role of heparan sulfate in inflammation, and the development of biomimetics as anti-inflammatory strategies.J Histochem Cytochem2018;66:321-36 PMCID:PMC5958377

[86] Hua R,Yan X.Syndecan-2 in colorectal cancer plays oncogenic role via epithelial-mesenchymal transition and MAPK pathway.Biomed Pharmacother2020;121:109630

[87] Popović A,Spajić B,Kruslin B.Expression and prognostic role of syndecan-2 in prostate cancer.Prostate Cancer Prostatic Dis2010;13:78-82

[88] Park CH,An JY.Abstract 1626: PMC309, a highly selective anti-VISTA antibody enhances T cell activation through blocking the interaction of T cells and myeloid derived suppressor cells (MDSC).Cancer Res2021;81:1626-1626

[89] ElTanbouly MA,Noelle RJ.VISTA: coming of age as a multi-lineage immune checkpoint.Clin Exp Immunol2020;200:120-30 PMCID:PMC7160665

[90] Guillaudeux T,Tarcha E.268 KVA 12.1 a novel fully human anti-VISTA antibody: clinical trial design in monotherapy and in combination with an anti-PD1 antibody.J ImmunoTherapy Cancer2021;9:A1-A1054

[91] Thisted T,Malhotra K,Kleschenko Y.228 Antagonistic pH-selective VISTA antibody SNS-101 potentiates anti-PD-1/PD-L1-induced anti-tumor immunity.J ImmunoTherapy Cancer2021;

[92] Pipeline iOmx therapeutics. Available from: https://iomx.com/pipeline [Last accessed on 15 June 2022].

[93] A study of safety, pharmacokinetics, pharmacodynamics of JNJ-61610588 in participants with advanced cancer. Available from: https://ClinicalTrials.gov/show/NCT02671955 [Last accessed on 15 June 2022].

[94] Phase 1 study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies. Available from: https://ClinicalTrials.gov/show/NCT04475523 [Last accessed on 15 June 2022].

[95] Scott F,Burvenich I,Guo N.324 Preclinical evaluation of anti-VISTA antibody CI-8993 in a syngeneic huVISTA-KI model.J ImmunoTherapy Cancer2021;

[96] Sasikumar PG,Adurthi S.PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy.Commun Biol2021;4:699 PMCID:PMC8187357

[97] Radhakrishnan V,Prabhash K,Nag S. Abstract P714: phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin lymphoma2018.

[98] First-In-Human (FIH) Study of W0180 as single agent and in combination with pembrolizumab in adults with locally advanced or metastatic solid tumors. Available from: https://ClinicalTrials.gov/show/NCT04564417 [Last accessed on 15 June 2022].

[99] A study of HMBD-002, a monoclonal antibody targeting VISTA, as monotherapy and combined with pembrolizumab. Available from: https://ClinicalTrials.gov/show/NCT05082610 [Last accessed on 15 June 2022].

[100] Thakkar D,Dharmadhikari B.Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.J Immunother Cancer2022;10:e003382

[101] Pilones KA,Daviaud C.Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.Oncoimmunology2020;9:1830524 PMCID:PMC7583495

[102] Tivol EA,Schweitzer A,Bluestone JA.Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.Immunity1995;3:541-7

[103] Waterhouse P,Timms E.Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.Science1995;270:985-8